OTX-CSI

About Ocular Therapeutix

Ocular Therapeutix's mission is to redefine the treatment of ophthalmic diseases by leveraging its proprietary hydrogel technology to create sustained-release therapies that reduce the high frequency of interventions required by current standards of care. The company has successfully transitioned to commercial operations with DEXTENZA® and is now on the cusp of a major value inflection with its lead candidate, AXPAXLI™ (axitinib implant), under FDA review for wet AMD. Its strategy centers on addressing the critical unmet need of treatment burden to improve patient adherence and visual outcomes, thereby capturing significant share in multi-billion dollar retinal markets.

Therapeutic Areas